Market Cap
$539.6M
BWAY
Brainsway Ltd.
$12.77 ▲ +1.35%
Prev close $12.60Market cap$539.6M
ConsensusStrong Buy
12-mo target$19.27 (+50.9%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)5 New Institutional Positions5 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on BWAY right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
35 funds
Inst. Value
$116.5M
Inst. Activity
5 buys / 5 sells
Insider Activity
$0.00 buy / $0.00 sell
SEC Reports
10
Press Releases
5
Price chart 30d -10.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 SEC Aug 12, 2026 SEC
BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and Neurology showing Dee
6-K — Impact 4/10
Sep 8, 2026 fda
Aug 27, 2026 SEC BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, a
BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70
6-K — Impact 6/10
Brainsway Ltd. furnished an August 2026 investor deck via Form 6-K, presenting strong H1 2026 financial results: revenue
6-K — Impact 6/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
188,968 shares ($2.9M)
Jun 30, 2026 Inst.
Jun 29, 2026 Press ARK Investment Management LLC — TRIM
142,500 shares ($2.2M)
BrainsWay presented positive real-world data showing 83.5% of comorbid PTSD/MDD patients responded to Deep TMS with a 52
Impact 6/10
Jun 15, 2026 Insider
Moiseyev Gilad sold 5,000 shares
Chief Technology Officer
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 7 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | BTIG | REITERATE | Buy | 53% |
| Sep 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 13, 2026 | Ladenburg Thalmann | MAINTAIN | Buy | 45% |
| Aug 12, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Jul 20, 2026 | BTIG | INITIATE | Buy | 53% |
| Jul 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Price targets
Where 3 covering analysts think BWAY trades over the next 12 months.
$19.27 +50.9% upside Strong Buy
Current$12.77 Low$18.80 Median$19.00 High$20.00 3 analysts
$18.80$20.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 7 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 5.7/10.Plus 5 press releases.
NEUTRAL6-K4/10
BrainsWay announced publication of a pilot study (n=12) in the Journal of Geriatric Psychiatry and N
Sep 9, 2026
BULLISH6-K6/10
BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Di
Aug 27, 2026
BULLISH6-K6/10
Brainsway Ltd. furnished an August 2026 investor deck via Form 6-K, presenting strong H1 2026 financ
Aug 12, 2026
BULLISH6-K7/10
BrainsWay reported a record Q2 2026 with revenue up 35% YoY to $17.1M, net income up 34% to $2.7M, a
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
fda
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in
Aug 12, 2026
earnings
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
Jul 29, 2026
earnings
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leade
Jul 16, 2026
contract
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to tr
Jun 29, 2026
fda
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most comm
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.09 | $0.07–$0.12 | 333.4% | +0.0% | 1↑ 1↓ | $0.0B | 3 |
| Next Q | $0.09 | $0.07–$0.13 | 46.2% | +3.7% | — | $0.0B | 3 |
| Current FY | $0.31 | $0.27–$0.38 | 70.4% | +0.0% | 2↑ 1↓ | $0.1B | 3 |
| Next FY | $0.51 | $0.38–$0.75 | 65.2% | +4.8% | 2↑ 0↓ | $0.1B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.087 | — |
| 7d ago | $0.087 | — |
| 30d ago | $0.087 | — |
| 60d ago | $0.095 | -0.008 |
| 90d ago | $0.087 | — |
Institutional ownership
Which big funds own BWAY (from quarterly 13F filings) and who is adding or trimming.
35 institutional holders with $116.5M total value (7,512,906 shares) as of 2026-Q2. Top holders: Valor, RENAISSANCE, Cresset.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Valor Management LLC | 5,314,950 | $82.4M | 70.8% | DOUBLED +100.0% |
| RENAISSANCE TECHNOLOGIES LLC | 475,920 | $7.4M | 6.3% | ADD +87.2% |
| Cresset Asset Management, LLC | 314,924 | $4.9M | 4.2% | DOUBLED +100.0% |
| MORGAN STANLEY | 188,968 | $2.9M | 2.5% | ADD +81.0% |
| ARK Investment Management LLC | 142,500 | $2.2M | 1.9% | TRIM -26.4% |
| SEI INVESTMENTS CO | 119,717 | $1.9M | 1.6% | TRIM -47.1% |
| UBS Group AG | 101,077 | $1.6M | 1.3% | DOUBLED +142.9% |
| TWO SIGMA INVESTMENTS, LP | 99,545 | $1.5M | 1.3% | TRIM -26.4% |
| ROYCE & ASSOCIATES LP | 97,033 | $1.5M | 1.3% | — |
| JPMORGAN CHASE & CO | 96,807 | $1.5M | 1.3% | DOUBLED +105.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 104,394 | 188,968 | +81.0% | $2.9M |
| ARK Investment Management LLC | TRIM | 193,686 | 142,500 | -26.4% | $2.2M |
| SEI INVESTMENTS CO | TRIM | 226,378 | 119,717 | -47.1% | $1.9M |
| JPMORGAN CHASE & CO | DOUBLED | 47,030 | 96,807 | +105.8% | $1.5M |
| Tidal Investments LLC | DOUBLED | 15,055 | 89,248 | +492.8% | $1.4M |
| CITADEL ADVISORS LLC | TRIM | 87,053 | 47,519 | -45.4% | $737.0K |
| Trexquant Investment LP | TRIM | 77,154 | 36,892 | -52.2% | $572.2K |
| NewEdge Advisors, LLC | DOUBLED | 3,522 | 18,830 | +434.6% | $292.1K |
| BARCLAYS PLC | ADD | 1,060 | 1,435 | +35.4% | $22.3K |
| JONES FINANCIAL COMPANIES LLLP | TRIM | 250 | 185 | -26.0% | $2.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
3 insiders, 12 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | Moiseyev Gilad | Chief Technology Officer | SELL | 5,000 | — | — |
| Jun 2, 2026 | Roth Yiftach | Chief Scientist | SELL | 1,000 | — | — |
| Jun 2, 2026 | Roth Yiftach | Chief Scientist | SELL | 2,000 | — | — |
| Jun 1, 2026 | Roth Yiftach | Chief Scientist | SELL | 2,000 | — | — |
| May 26, 2026 | Mitrany Rayten Michal Ety | Director | SELL | 7,980 | — | — |
| May 25, 2026 | Mitrany Rayten Michal Ety | Director | SELL | 10,000 | — | — |
| May 25, 2026 | Moiseyev Gilad | Chief Technology Officer | EXERCISE | 7,500 | — | — |
| May 25, 2026 | Moiseyev Gilad | Chief Technology Officer | TAX W/H | 1,902 | — | — |
| May 20, 2026 | Mitrany Rayten Michal Ety | Director | EXERCISE | 17,500 | — | — |
| May 20, 2026 | Mitrany Rayten Michal Ety | Director | TAX W/H | 6,080 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BWAY.
Shares short
199,566
Settlement Sep 15, 2026
Change vs prior
-4.1%
Semi-monthly cycle
Days to cover
2.2
At avg daily volume
Of shares outstanding
≈0.5%
Estimate — not % of float
All BWAY filing & press-release reports (15)
- 6-K reportSep 9, 2026
- 6-K reportAug 27, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- 6-K reportJul 20, 2026
- 6-K reportJul 16, 2026
- 6-K reportJul 3, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 13, 2026
- PRESS-RELEASE reportMar 26, 2026
- 6-K reportMar 26, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 4, 2026